Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -132,774 | -93,767 | -176,937 | -127,442 | -81,891 |
| Depreciation Amortization | 34 | 15 | 49 | 36 | 37 |
| Accounts payable and accrued liabilities | -11,656 | -8,311 | 5,070 | -7,824 | 3,155 |
| Other Working Capital | -24,722 | -10,137 | 5,866 | -3,473 | 2,221 |
| Other Operating Activity | 60,537 | 57,598 | 24,734 | 30,559 | 7,935 |
| Operating Cash Flow | $-108,581 | $-54,602 | $-141,218 | $-108,144 | $-68,544 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -594 | -385 | -24 | -21 | -4 |
| Other Investing Activity | 0 | 0 | 0 | 0 | 5,644 |
| Investing Cash Flow | $-594 | $-385 | $-24 | $-21 | $5,640 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | N/A | -33 |
| Common Stock Issued | 204,342 | 199,684 | 8,912 | 8,912 | 8,781 |
| Other Financing Activity | -1,504 | -1,504 | 0 | 0 | 0 |
| Financing Cash Flow | $202,838 | $198,180 | $8,912 | $8,912 | $8,748 |
| Exchange Rate Effect | -3,405 | -2,496 | 5,052 | -168 | -5,846 |
| Beginning Cash Position | 340,450 | 340,450 | 467,728 | 467,728 | 478,164 |
| End Cash Position | 430,708 | 481,147 | 340,450 | 368,307 | 418,163 |
| Net Cash Flow | $90,258 | $140,697 | $-127,278 | $-99,421 | $-60,001 |
| Free Cash Flow | |||||
| Operating Cash Flow | -108,581 | -54,602 | -141,218 | -108,144 | -68,544 |
| Capital Expenditure | -594 | -385 | -24 | -21 | -4 |
| Free Cash Flow | -109,175 | -54,987 | -141,242 | -108,165 | -68,548 |